Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2020-12-08 Regulatory Filings
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
PTX Extends COVID-19 Testing Program with Doherty Institute 3 pages 343.8KB
Regulatory Filings Classification · 95% confidence The document is a press release dated December 9, 2020, from Prescient Therapeutics, discussing the extension of a COVID-19 antiviral testing program with the Doherty Institute. It provides background on the company's therapies and research programs, including COVID-19 related antiviral testing. The document does not contain financial statements, detailed financial performance data, or regulatory filings. It is a corporate announcement about ongoing research activities and plans rather than a formal financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or management report. The content is primarily an update on research/testing activities and company plans, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other specific categories.
2020-12-08 English
Amendment of Results of Annual General Meeting 6 pages 525.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Amendment of Results of Annual General Meeting' and provides detailed voting results for resolutions passed at the Annual General Meeting held on 24 November 2020. It includes proxy votes, poll results, and resolution outcomes. The content focuses on the official voting results and amendments to those results, which is typical of a Declaration of Voting Results document. There is no indication that this is the full AGM presentation or materials, nor is it a full annual report or financial statement. The document is not a proxy solicitation or remuneration report. The detailed voting results and the nature of the content align with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is sufficient and contains substantive voting data, confirming it is not merely an announcement of a report but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2020-11-24 English
AGM Presentation 32 pages 2.2MB
AGM Information Classification · 95% confidence The document is titled 'A YEAR OF TRANSFORMATION' and references the 'Annual General Meeting November 2020'. It contains forward-looking statements, executive summaries, detailed descriptions of clinical trials, drug development progress, and strategic updates. The content is structured as a presentation with slides, including pipeline updates, clinical trial statuses, and business developments. The presence of forward-looking statements and the format strongly indicate this is a presentation given at an Annual General Meeting (AGM). There is no indication that this is a full annual report (10-K) or an earnings release (ER). The document is lengthy (15,000 characters) and detailed but is clearly a presentation rather than a formal report. Therefore, the most appropriate classification is AGM Information (AGM-R).
2020-11-23 English
Results of Annual General Meeting 3 pages 367.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is dated 24 November 2020 and is addressed to the ASX Limited Market Announcements Office. It explicitly states it is providing the "RESULTS OF 2020 ANNUAL GENERAL MEETING" and includes detailed voting results for multiple resolutions passed at the AGM. The content includes proxy votes, percentages for and against each resolution, and whether each resolution was carried or not. There is no indication that this is a full report or presentation, but rather an official announcement of the voting results from the AGM. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length is 5646 characters, which is sufficient to include detailed voting results rather than just a brief notice. Therefore, the correct classification is DVA with high confidence.
2020-11-23 English
Constitution 69 pages 800.0KB
Governance Information Classification · 100% confidence The document is titled 'Constitution of Prescient Therapeutics Limited' and contains detailed sections on company governance, share capital, directors' powers, meetings, voting, dividends, and other corporate governance matters. It is a legal and governance document outlining the internal rules and structure of the company rather than a financial report, announcement, or regulatory filing. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. The content aligns with governance information about the company's constitution and internal rules. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial and contains the full constitution text, not just an announcement or summary.
2020-11-23 English
Prescient Receives $1.03m R&D Tax Rebate 3 pages 302.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Prescient Therapeutics regarding the receipt of a $1.03 million R&D tax rebate for the 2019/2020 financial year. It references the rebate being accounted for in the company's 2020 Annual Financial Report and the upcoming December 2020 Appendix 4C. The content focuses on the announcement of the rebate receipt and provides background on the company's operations and therapies. There are no detailed financial statements, comprehensive financial performance data, or management analysis typically found in an Annual Report or Interim Report. The document is relatively short (8474 characters) and serves as a news release or update rather than a full financial report. It does not fit into categories like Earnings Release, Capital Update, or Management Reports. It is primarily an announcement of a financial event (receipt of tax rebate) and related company information. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-11-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.